America Stem Cell, ASC-101 Orphan Drug Designation

Mar. 31, 2011 5:53 PM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Special Situations, Contrarian

Contributor Since 2009

Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning and Communication at Curis (2001-2002), HQCM focusing on healthcare investments (NYSE:HQH/HQL) from (1985-2001)and founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA. Past experiences include Thermo Scientific, SWEC following 5 years at the FBI. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities' graduate business schools.
The FDA has granted Orphan Drug Designation to America Stem (ASC) Cell’s ASC-101 to improve homing to bone marrow (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.
  • ASC is commencing a Phase I/IIa clinical trial for the treatment of advanced hematological cancers at the University of Texas M.D. Anderson Cancer Center in Houston.

ASC-101 and ASC-201 are designed to improve the engraftment of stem cells to target organs and increase their therapeutic potential. Hematopoietic stem cells derived from cord blood, peripheral blood, and bone marrow is used to treat 70+ diseases.

The Bottom Line: America Stem Cell (ASC) is a privately held company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell transplants. ASC has established a number of strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, and VidaCord Technologia Biomedica. Orphan drug status confirms the importance of this new novel treatment approach to improve outcomes for patients with serious, life-threatening cancers and other disorders for which hematopoietic stem cell transplant is prescribed. The  designation will confer financial benefits and incentives, such as potential grant funding to defray the cost of clinical testing, tax credits for the costs of clinical research, 7 year period of exclusive marketing after approval and Waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.